Published in J Clin Invest on May 01, 1997
Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol (2001) 2.75
Platelets as cellular effectors of inflammation in vascular diseases. Circ Res (2013) 2.62
Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest (2003) 2.27
Mechanisms of endothelial cell attachment, proliferation, and differentiation on 4 types of platinum-based endovascular coils. World Neurosurg (2013) 2.09
Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res (2010) 1.96
Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One (2010) 1.94
Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood (2008) 1.83
The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol (2009) 1.78
Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest (2008) 1.77
Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest (1998) 1.73
Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol (2008) 1.51
Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol (2010) 1.43
Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther (2005) 1.28
Platelet-derived exosomes induce endothelial cell apoptosis through peroxynitrite generation: experimental evidence for a novel mechanism of septic vascular dysfunction. Crit Care (2007) 1.26
Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis. Semin Immunopathol (2011) 1.26
EVpedia: a community web portal for extracellular vesicles research. Bioinformatics (2014) 1.21
Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun (2012) 1.18
Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol (2012) 1.17
The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol (2010) 1.08
Proteomic and functional characterisation of platelet microparticle size classes. Thromb Haemost (2009) 1.08
Voltage-gated proton channels. Cell Mol Life Sci (2008) 1.06
Microparticle-associated endothelial protein C receptor and the induction of cytoprotective and anti-inflammatory effects. Haematologica (2009) 1.05
Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am J Pathol (2006) 1.05
Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation (2010) 1.04
Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice. Infect Immun (2000) 1.03
CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation. Br J Haematol (2008) 1.00
Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation? J Cell Mol Med (2012) 0.99
Endovascular laser–tissue interactions and biological responses in relation to endovenous laser therapy. Lasers Med Sci (2014) 0.96
Microparticles as mediators and biomarkers of rheumatic disease. Rheumatology (Oxford) (2012) 0.93
Microvesicles: potential markers and mediators of endothelial dysfunction. Curr Opin Endocrinol Diabetes Obes (2012) 0.93
Horizontal transfer of RNA and proteins between cells by extracellular microvesicles: 14 years later. Clin Transl Med (2016) 0.92
Microparticles mediate hepatic ischemia-reperfusion injury and are the targets of Diannexin (ASP8597). PLoS One (2014) 0.92
Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA. Proc Natl Acad Sci U S A (2015) 0.92
Platelets participate in synovitis via Cox-1-dependent synthesis of prostacyclin independently of microparticle generation. J Immunol (2011) 0.89
Platelet microparticle levels: a biomarker of thromboangiitis obliterans (Buerger's disease) exacerbation. J Cell Mol Med (2009) 0.89
The role of platelets in the recruitment of leukocytes during vascular disease. Platelets (2015) 0.87
Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies. J Lipid Res (2014) 0.87
Microparticles in endothelial cell and vascular homeostasis: are they really noxious? Haematologica (2009) 0.87
Endothelial microparticles: sophisticated vesicles modulating vascular function. Vasc Med (2013) 0.87
The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation. Mod Rheumatol (2008) 0.85
Endocytosis and intracellular processing of platelet microparticles by brain endothelial cells. J Cell Mol Med (2012) 0.85
Platelet function and Isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family? J Biomed Sci (2010) 0.85
Platelet-derived microparticles and the potential of glycoprotein IIb/IIIa antagonists in treating acute coronary syndrome. Tex Heart Inst J (2009) 0.84
Microparticles--messengers of biological information. J Cell Mol Med (2010) 0.84
Breaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticles. Front Immunol (2015) 0.84
Circulating annexin V positive microparticles in patients after successful cardiopulmonary resuscitation. Crit Care (2011) 0.84
Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population. Cytometry B Clin Cytom (2010) 0.81
Platelet storage and transfusions: new concerns associated with an old therapy. Drug Discov Today Dis Mech (2011) 0.80
Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood (2006) 0.80
Soluble TLT-1 modulates platelet-endothelial cell interactions and actin polymerization. Blood Coagul Fibrinolysis (2010) 0.80
Microparticles: new light shed on the understanding of venous thromboembolism. Acta Pharmacol Sin (2014) 0.78
Circulating membrane-derived microvesicles in redox biology. Free Radic Biol Med (2014) 0.78
Selenium prevents microparticle-induced endothelial inflammation in patients after cardiopulmonary resuscitation. Crit Care (2015) 0.78
Circulating Endothelial Microparticles: A Key Hallmark of Atherosclerosis Progression. Scientifica (Cairo) (2016) 0.77
Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis. Front Pharmacol (2016) 0.76
Antiplatelet Agents Inhibit the Generation of Platelet-Derived Microparticles. Front Pharmacol (2016) 0.75
Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer. Crit Rev Oncog (2015) 0.75
Extracellular vesicles in renal disease. Nat Rev Nephrol (2017) 0.75
Levels of activated platelet-derived microvesicles in patients with soft tissue sarcoma correlate with an increased risk of venous thromboembolism. BMC Cancer (2017) 0.75
Metastatic state of parent cells influences the uptake and functionality of prostate cancer cell-derived extracellular vesicles. J Extracell Vesicles (2017) 0.75
Modulation of platelet-derived microparticles to adhesion and motility of human rheumatoid arthritis fibroblast-like synoviocytes. PLoS One (2017) 0.75
Pulmonary Extracellular Vesicles as Mediators of Local and Systemic Inflammation. Front Cell Dev Biol (2017) 0.75
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A (1999) 4.16
Acute admissions to medical beds. J R Coll Gen Pract (1972) 3.80
Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology (2008) 3.54
Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med (2005) 3.13
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Platelet activation in unstable coronary disease. N Engl J Med (1986) 2.60
Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock. Cell (2001) 2.59
Effects of vitamin E on lipid peroxidation in healthy persons. JAMA (2001) 2.58
The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med (1989) 2.36
No evidence for lipid peroxidation in severe preeclampsia. Am J Obstet Gynecol (2001) 2.28
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest (2001) 2.19
Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest (1981) 2.18
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest (1983) 2.13
Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci (2007) 2.11
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther (1999) 2.10
Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med (1984) 2.00
Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med (1998) 1.98
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood (1987) 1.96
Activation of caspase 3 (CPP32)-like proteases is essential for TNF-alpha-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J Immunol (1998) 1.82
Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation (1999) 1.79
Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol (2000) 1.79
Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest (2000) 1.78
MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med (2004) 1.77
Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation (1991) 1.74
Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation (1996) 1.74
Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation (1983) 1.73
Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med (1984) 1.73
Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest (1998) 1.73
Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol (2001) 1.71
A double blind placebo controlled crossover study of prostacyclin in man. Life Sci (1979) 1.67
Occupational asthma in newly employed workers in intensive swine confinement facilities. Eur Respir J (2004) 1.63
Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem (1993) 1.59
Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med (1991) 1.58
Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet (1990) 1.56
Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest (1999) 1.55
Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation (1997) 1.54
Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol (1997) 1.53
Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem (1999) 1.53
Two polymorphisms in the human lipoprotein lipase (LPL) gene. Nucleic Acids Res (1987) 1.51
Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation (1988) 1.49
Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. J Vasc Surg (1999) 1.49
Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med (2000) 1.48
Dipyridamole. N Engl J Med (1987) 1.48
Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation (2001) 1.46
Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine. Proc Natl Acad Sci U S A (1999) 1.45
Effects of celecoxib on major prostaglandins in asthma. Clin Exp Allergy (2010) 1.45
Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med (1988) 1.45
IPF2alpha-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci U S A (1998) 1.43
Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radic Biol Med (2005) 1.42
8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation (1997) 1.41
Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol (2007) 1.41
Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.38
Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A (1990) 1.38
Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs. Circulation (1997) 1.38
Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest (1997) 1.38
Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J Neurosci (2011) 1.37
In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med (1986) 1.36
11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A (1986) 1.35
Protection against Fas receptor-mediated apoptosis in hepatocytes and nonparenchymal cells by a caspase-8 inhibitor in vivo: evidence for a postmitochondrial processing of caspase-8. Toxicol Sci (2000) 1.30
Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest (2001) 1.29
The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem (1990) 1.29
The isoprostanes in biology and medicine. Trends Endocrinol Metab (2001) 1.29
Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2 alpha. J Biol Chem (1995) 1.28
Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation (1987) 1.27
Validation of a new quality of life measure for children with epilepsy. Epilepsia (2000) 1.25
Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest (1999) 1.25
Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation (1997) 1.23
Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem (2001) 1.23
Glutathione peroxidase-deficient mice are more susceptible to neutrophil-mediated hepatic parenchymal cell injury during endotoxemia: importance of an intracellular oxidant stress. Hepatology (1999) 1.23
Eicosanoid forming enzyme mRNA in human tissues. Analysis by quantitative polymerase chain reaction. J Biol Chem (1991) 1.22
Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest (1983) 1.21
Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway. J Biol Chem (1999) 1.21
Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation (2000) 1.21
Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med (1988) 1.19
Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. Proc Natl Acad Sci U S A (1990) 1.19
Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease. Curr Alzheimer Res (2010) 1.18
Nomenclature of isoprostanes: a proposal. Prostaglandins (1997) 1.17
Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci U S A (1990) 1.17
Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res (1987) 1.15